Navigation Links
Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI's Programmable, Pulsatile, Passive Transdermal Drug Delivery Device - ChronoDose

BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/ -- Chrono Therapeutics Inc. (CTI) announced today the successful completion of its first phase human clinical trial of its programmable, pulsatile, passive transdermal drug/device combination product: ChronoDose(TM). CTI intends to publish this clinical data in leading scientific and medical journals by year end.


The trial was conducted between February and April 2007 at the University Hospital Basel, Switzerland, Division of Clinical Pharmacology and Toxicology. Georgios Imanidis, PhD, of the University of Basel was the Principal Investigator on behalf of CTI.

This study was an open, randomized, three period, single-center, dose- escalation study. Thirty-six independent human transdermal tests were conducted on male volunteers using wristwatch-like ChronoDose(TM) devices. The trial successfully proved the efficacy of the device on human subjects using its model drug compound. The dose escalation trial showed statistically significant modulation and control of the dosing profiles. Using low, medium and high concentrations, for 16 hours, the model drug permeated each subject's skin on multiple occasions, resulting in clear and distinct peaks and troughs of therapeutically effective and well-targeted blood plasma concentration levels. A non-compartmental and compartmental model based analysis of pharmacokinetics will be utilized. Local and systemic tolerability of the model drug after its transdermal administration was better than planned.

Dr. Georgios Imanidis commented, "CTI has for the first time in transdermal drug delivery history successfully completed a significant human trial with a passive, automated and programmable multiple dosing transdermal device syste m. We are extremely pleased with the excellent results".

Guy DiPierro, CEO and President of CTI noted, "This solid and convincing clinical data along with initial human data generated last summer will help us to rapidly commercialize our initial drug product. We are particularly pleased that ChronoDose(TM) produced targeted blood plasma concentrations as accurately as it did and at the intended time periods."


    -- Chrono Therapeutics Inc. (CTI) was founded in late 2003 to become the

       global leader in Chrono-Pharmacologically based prescription and OTC

       drug delivery.

    -- Today CTI is a specialty pharmaceutical company that developing,

       manufacturing and commercializing Chrono-Pharmacologically based drug


    -- CTI has created and patented the world's first automated and

       programmable, passive transdermal drug delivery device-ChronoDose(TM)

    -- ChronoDose

        -- Dramatically improves therapies

        -- Significantly decreases symptoms and side effects

        -- Ensures less built-up tolerance to the drug


Annually, over 20% of hospital admissions result from patient non-compliance, costing the healthcare industry over $100 billion/year. ChronoDose(TM) offers a revolutionary step forward in guaranteed patient compliance, especially for the elderly, hospitalized, or the mentally ill.


    Chrono Therapeutics Inc.

    Guy DiPierro, President and Chief Executive Officer

    Phone: (609) 838 2572



CONTACT: Guy DiPierro, President and Chief Executive Officer of ChronoTherapeutics Inc., +1-609-838-2572,

Web site: http://www.chr

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
9. Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme
Post Your Comments:
(Date:11/30/2015)... 30, 2015 iCAD, Inc. (Nasdaq: ... its latest solutions for advanced image analysis and ... at the Radiological Society of North American (RSNA) ... from November 29 to December 4, 2015. ... iReveal®, an automated breast density assessment solution, PowerLook® ...
(Date:11/30/2015)... 30, 2015 Booth #4303 – The Imaging Components ... exhibit a broader array of products in a new booth ... North America in Chicago ... will feature X-ray components "At the Heart of Imaging." Products ... products from Varian,s Claymount brand, and computer-aided diagnostic software from ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate ... the 57 th American Society of Hematology (ASH) ... and myelomas as well as supportive care, including key ... to personalized cell therapies. The ASH Annual Meeting will ... . Novartis Oncology . "We will ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... anxiety, illness, infection or even a need for eyeglasses can sometimes cause headaches, but ... pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said that while headaches ... headaches that don’t go away, that don’t have any other reason, even after you’ve ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... driverless vehicle experience this summer, ushering in a new era of publicly accessible ... and electric shuttle, will continue to offer guests an up-close look at the ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Catalyst continuing education course in Dallas, TX, on January 29 and 30, 2016. ... to improve the functions of their practices, to learn how to better succeed ...
(Date:11/30/2015)... ... November 30, 2015 , ... A ... of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of ... Their study showed that small molecule analogs that target the functions of SecA, ...
Breaking Medicine News(10 mins):